Provided by Tiger Fintech (Singapore) Pte. Ltd.

Adial Pharmaceuticals

0.3022
-0.0329-9.82%
Post-market: 0.2948-0.0074-2.45%16:40 EDT
Volume:3.67M
Turnover:1.14M
Market Cap:4.77M
PE:-0.19
High:0.3300
Open:0.3092
Low:0.3000
Close:0.3351
Loading ...

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

GlobeNewswire
·
25 Feb

EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder

Benzinga
·
25 Feb

BRIEF-Adial Pharmaceuticals Granted New U.S. Patent On Method To Identify Genetic Markers In Alcohol or Opioid-Related Disorders

Reuters
·
19 Feb

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of Its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

THOMSON REUTERS
·
19 Feb

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

GlobeNewswire
·
19 Feb

Adial Pharmaceuticals awarded new U.S. patent on genotype-specific treatment

TIPRANKS
·
12 Feb

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

THOMSON REUTERS
·
12 Feb

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

GlobeNewswire
·
12 Feb

Adial Pharmaceuticals announce clinical study results from AD04-103 study

TIPRANKS
·
29 Jan

Adial Pharmaceuticals Announces Positive Clinical Study Results From the Ad04-103 Pharmacokinetics Study of Ad04 for the Treatment of Alcohol Use Disorder

THOMSON REUTERS
·
29 Jan

Adial Pharmaceuticals Inc - Ad04 Safety and Tolerability Consistent With Ondansetron

THOMSON REUTERS
·
29 Jan

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

GlobeNewswire
·
29 Jan

EXCLUSIVE: Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder

Benzinga
·
29 Jan

Adial Pharmaceuticals Highlights AD04 for Alcohol Use Disorder

TIPRANKS
·
09 Jan